Dissecting the Nucleoside Antibiotics as Universal Translation Inhibitors

Area of Science:

• Microbiology and Molecular Biology
• Natural Product Chemistry
• Drug Discovery and Development

Background:

• Natural products are a primary source of antibacterial leads, targeting essential bacterial processes.
• Gram-negative bacteria present significant challenges for antibiotics due to their double membrane and efflux systems.
• The bacterial ribosome is a key target, but selective inhibition of prokaryotic translation over eukaryotic is difficult.

Purpose of the Study:

• To investigate the natural product amicetin as a potential selective inhibitor of the bacterial ribosome.
• To explore a novel mechanism of action involving interaction with ribosomal protein uL16.
• To develop strategies for stabilizing and improving the cell penetrance of amicetin for therapeutic use.

Main Methods:

• Analysis of amicetin's interaction with the bacterial ribosome, focusing on its unique binding site.
• Chemical modification of the amicetin scaffold to enhance stability and simplify its structure.
• Assessment of improved amicetin derivatives for bacterial cell penetration and selective ribosomal inhibition.

Main Results:

• Amicetin demonstrates a mechanism distinct from other nucleoside antibiotics, potentially targeting ribosomal protein uL16.
• Initial modifications show promise in stabilizing the complex amicetin structure.
• The study lays the groundwork for developing simplified amicetin analogs with enhanced bacterial targeting.

Conclusions:

• Amicetin offers a promising avenue for a new class of antibiotics targeting the bacterial ribosome selectively.
• Modification of the amicetin scaffold is crucial for overcoming its chemical instability and improving efficacy.
• This research could lead to novel therapeutics against challenging bacterial infections, particularly in Gram-negative pathogens.